Environmentally benign decarboxylative <i>N</i>-, <i>O</i>-, and <i>S</i>-acetylations and acylations
作者:Santanu Ghosh、Anisha Purkait、Chandan K. Jana
DOI:10.1039/d0gc03731a
日期:——
An operationally simple and general method for acetylation and acylation of a wide variety of substrates (amines, alcohols, phenols, thiols, and hydrazones) has been reported. Meldrum's acid and its derivatives have been used as an air-stable, non-volatile, cost-effective, and easy to handle acetylating/acylating agent. Easily separable byproducts (CO2 and acetone) allowed the isolation of analytically
ARYL DIHYDROPYRIDINONE AND PIPERIDINONE MGAT2 INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:US20130143843A1
公开(公告)日:2013-06-06
The present invention provides compounds of Formula (I):
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
A Novel One-pot Method for Reductive Conversion of Azides to Acyl Amines with Acetic Anhydride and Trimethyl Chlorosilane
作者:Apurba Barua、Ghanashyam Bez、Nabin C. Barua
DOI:10.1055/s-1999-2673
日期:1999.5
A combination of acetic anhydride and chloro-trimethylsilane has been shown to effect the conversion of a variety of azides to the corresponding acetylated amines in excellent yields without affecting other functional groups such as ether, ester, halide etc.
acetone-water media in the presence of the lipase from Pseudomonasfluorescens was found to be accompanied by the coprecipitation of the enzyme. Within the lyophilized coprecipitates, the lipase exhibits a high catalytic activity and enantioselectivity in the reaction of (1RS)-phenylethanol acetylation with vinyl acetate in t-butyl methyl ether. In order of increasing lipase activity, the coprecipitates can
[EN] LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] CONJUGUÉS LIPIDIQUES POUR L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUES
申请人:ARROWHEAD PHARMACEUTICALS INC
公开号:WO2022056273A1
公开(公告)日:2022-03-17
Disclosed herein are compounds according to Formula (I) comprising PK/PD modulators for delivery of oligonucleotide-based agents, e.g., double stranded RNAi agents, to certain cell types, such for example skeletal muscle cells, in vivo. The PK/PD modulators disclosed herein, when conjugated to an oligonucleotide-based therapeutic or diagnostic agent, such as an RNAi agent, can enhance the delivery of the composition to the specified cells being targeted to facilitate the inhibition of gene expression in those cells.